severe asthma – Discover Pharma

Welcome to Discover Pharma! Today is : October 18, 2026

severe asthma

Advanced Therapies,Clinical & Regulatory,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Trixeo approved in EU for asthma
AstraZeneca’s Trixeo has been approved in the EU as a [...]

September 30, 2026
Digital & Data,Drug Discovery & Development,Research & Development,Therapeutic Areas
Passive cough monitoring linked to worsening asthma symptoms
Contactless monitoring of nocturnal cough has been linked to worsening [...]

September 16, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas
Tezspire meets Phase 3 endpoints in eosinophilic esophagitis
AstraZeneca and Amgen’s Tezspire has met both co-primary and key [...]

August 28, 2026
Clinical & Regulatory,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Therapeutic Areas
Exdensur approved by European Commission for severe asthma and chronic rhinosinusitis with nasal polyps
GSK announced that the European Commission has approved Exdensur (depemokimab) [...]

May 5, 2026

main menu

recent posts

get connected

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK